FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Touts ImportShield Results

FDA says its new ImportShield program improved processing speed and volume capacity while reducing staff hours in its first four months in operation.

latest-news-card-1
Medical Devices

AdvaMed Urges FDA to Narrow Guidance on Device QMS

Advanced Medical Technology Association urges FDA to narrow and clarify a draft guidance on quality management system information, warning that the cu...

latest-news-card-1
Biologics

Moderna/Merck Report Positive Data on Melanoma Vaccine

Moderna and Merck report updated five-year follow-up data that show their personalized mRNA cancer vaccine candidate, intismeran autogene, significant...

Human Drugs

Objectionable Conditions in Prodrome Sciences BIMO Inspection

FDA warns Temecula, CA-based Prodrome Sciences USA about violations in its conduct of a clinical trial without submitting an IND.

latest-news-card-1
Human Drugs

Guide on Endpoints for Multiple Myeloma Accelerated Approval

FDA posts a draft guidance outlining how drug developers can use minimal residual disease and complete response as primary endpoints in multiple myelo...

latest-news-card-1
Biologics

FDA Seeks More Data on Capricor Cell Therapy

FDA asks Capricor Therapeutics for a full clinical study report from the companys Phase 3 HOPE-3 trial as part of its ongoing BLA review for Deramioce...

latest-news-card-1
Human Drugs

ICH Drug Submission Quality Information Guidance

FDA publishes for review and comment the International Council for Harmonization M4Q(R2) guidance establishing the location and structure of quality i...

latest-news-card-1
Human Drugs

4 CGMP Issues at Integrity Partners Facility

FDA warns Integrity Partners St. Louis, MO-based Chemisphere drug manufacturing facility about CGMP issues in its production of finished drugs as a co...

latest-news-card-1
Biologics

Valneva Withdraws BLA for Chikungunya Vaccine

Valneva says it has voluntarily withdrawn its BLA for Ixchiq, the companys chikungunya vaccine, based on FDA safety-related restrictions on the produc...

latest-news-card-1
Human Drugs

Celcuity NDA Gets Priority Review for Breast Cancer

FDA accepts for priority review a Celcuity NDA for gedatolisib in patients with hormone receptorpositive, HER2-negative, PIK3CA wild-type advanced bre...